David Robertson
David Robertson is researcher at MRC-University of Glasgow Centre for Virus Research.
1. Project: COVID-19 Genomics UK (COG-UK) Consortium
Summary: The COVID-19 Genomics UK (COG-UK) Consortium is a collaboration between the NHS, Public Health England and other UK public health agencies, the Wellcome Sanger Institute, University of Cambridge and other academic institutions. The COVID-19 Genomics UK (COG-UK) Consortium aims to increase the current capacity for SARS-CoV-2 genetic sequencing in the UK. This sequencing data will be used to understand the epidemiology and spread of the virus, and to monitor and evaluate interventions for COVID-19. SARS-CoV-2 genomic data will be integrated with NHS electronic health records and other existing genomic data to generate insights into susceptibility to COVID-19. From within the DPHPC, Professor John Danesh is a member of the COG-UK Steering Group, Dr Ewan Harrison will serve as the Scientific Project Manager and Dr Michael Chapman will lead the health informatics component.
2. Project: ISARIC - Coronavirus Clinical Characterisation Consortium.
3. Project: Viral and Immunological Correlates of Clinical Severity and Response to Anti-Viral Therapy for COVID-19
Summary: The clinical outcome of COVID-19 is ultimately determined by viral replication in the face of the host immunity. The latter can either control viral infection or exacerbate disease due to uncontrolled inflammatory processes that damages tissues. Hence, in order to establish the efficacy of antiviral therapies and determine whether stratification can aid clinical decisions in COVID19 patients, the study needs to identify correlates of disease severity and response to treatment. This proposal aims to fully determine the dynamic viral and immunological changes occurring during the different clinical stages of COVID-19. They will use a clinical trial for Favipiravir (GETAFIX, GLA3), an antiviral drug as their test case to develop their biomarkers but can roll this project out to support other trials within ASTERIX (GLA2). The study is led by Professor Carl Goodyear, University of Glasgow.
Co-investigators and institutions at University of Glasgow:
Professor Massimo Palmarini
Professor Iain McInnes
Professor Brian Willett
Professor Emma Thomson
Professor Gerard Graham
Professor Paul Garside
Professor Naveed Sattar
Professor Andrew Biankin
Professor David Robertson
Dr Janet Scott
Dr Antonia Ho
Dr Thomas Otto
Dr Ana Da Silva Filipe
Co-investigators and institutions at GGCHB NHS:
Dr Michael Murphy
Funder: Chief Scientist Office
Total award: £319,473
1. Project: COVID-19 Genomics UK (COG-UK) Consortium
Summary: The COVID-19 Genomics UK (COG-UK) Consortium is a collaboration between the NHS, Public Health England and other UK public health agencies, the Wellcome Sanger Institute, University of Cambridge and other academic institutions. The COVID-19 Genomics UK (COG-UK) Consortium aims to increase the current capacity for SARS-CoV-2 genetic sequencing in the UK. This sequencing data will be used to understand the epidemiology and spread of the virus, and to monitor and evaluate interventions for COVID-19. SARS-CoV-2 genomic data will be integrated with NHS electronic health records and other existing genomic data to generate insights into susceptibility to COVID-19. From within the DPHPC, Professor John Danesh is a member of the COG-UK Steering Group, Dr Ewan Harrison will serve as the Scientific Project Manager and Dr Michael Chapman will lead the health informatics component.
2. Project: ISARIC - Coronavirus Clinical Characterisation Consortium.
3. Project: Viral and Immunological Correlates of Clinical Severity and Response to Anti-Viral Therapy for COVID-19
Summary: The clinical outcome of COVID-19 is ultimately determined by viral replication in the face of the host immunity. The latter can either control viral infection or exacerbate disease due to uncontrolled inflammatory processes that damages tissues. Hence, in order to establish the efficacy of antiviral therapies and determine whether stratification can aid clinical decisions in COVID19 patients, the study needs to identify correlates of disease severity and response to treatment. This proposal aims to fully determine the dynamic viral and immunological changes occurring during the different clinical stages of COVID-19. They will use a clinical trial for Favipiravir (GETAFIX, GLA3), an antiviral drug as their test case to develop their biomarkers but can roll this project out to support other trials within ASTERIX (GLA2). The study is led by Professor Carl Goodyear, University of Glasgow.
Co-investigators and institutions at University of Glasgow:
Professor Massimo Palmarini
Professor Iain McInnes
Professor Brian Willett
Professor Emma Thomson
Professor Gerard Graham
Professor Paul Garside
Professor Naveed Sattar
Professor Andrew Biankin
Professor David Robertson
Dr Janet Scott
Dr Antonia Ho
Dr Thomas Otto
Dr Ana Da Silva Filipe
Co-investigators and institutions at GGCHB NHS:
Dr Michael Murphy
Funder: Chief Scientist Office
Total award: £319,473